How to buy InflaRx N-V stock

InflaRx N.V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 43 staff and has a market cap (total outstanding shares value) of USD0.00.

InflaRx N-V share price

Use our graph to track the performance of IFRX stocks over time.

InflaRx N-V shares at a glance

• Key figures

Information last updated 2021-03-18.

52-week range	USD$2.98 - USD$9.70
50-day moving average	USD$5.11
200-day moving average	USD$4.77
Wall St. target price	USD$10.62
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.08

Buy InflaRx N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy InflaRx N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of InflaRx N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InflaRx N-V financials

Gross profit TTM	USD$0
Return on assets TTM	-20.39%
Return on equity TTM	-36.43%
Profit margin	0%
Book value	$7.20
Market capitalisation	USD$194.6 million

TTM: trailing 12 months

Shorting InflaRx N-V shares

There are currently 429,991 InflaRx N-V shares held short by investors – that's known as InflaRx N-V's "short interest". This figure is 8% down from 467,149 last month.

There are a few different ways that this level of interest in shorting InflaRx N-V shares can be evaluated.

InflaRx N-V's "short interest ratio" (SIR)

InflaRx N-V's "short interest ratio" (SIR) is the quantity of InflaRx N-V shares currently shorted divided by the average quantity of InflaRx N-V shares traded daily (recently around 443289.69072165). InflaRx N-V's SIR currently stands at 0.97. In other words for every 100,000 InflaRx N-V shares traded daily on the market, roughly 970 shares are currently held short.

However InflaRx N-V's short interest can also be evaluated against the total number of InflaRx N-V shares, or, against the total number of tradable InflaRx N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InflaRx N-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 InflaRx N-V shares in existence, roughly 10 shares are currently held short) or 0.0176% of the tradable shares (for every 100,000 tradable InflaRx N-V shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InflaRx N-V.

Find out more about how you can short InflaRx N-V stock.

InflaRx N-V share dividends

We're not expecting InflaRx N-V to pay a dividend over the next 12 months.

InflaRx N-V share price volatility

Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $2.98 up to $9.6979. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.5145. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).

InflaRx N-V overview

InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.

Frequently asked questions

• What percentage of InflaRx N-V is owned by insiders or institutions?

  Currently 25.513% of InflaRx N-V shares are held by insiders and 14.778% by institutions.

• How many people work for InflaRx N-V?

  Latest data suggests 43 work at InflaRx N-V.

• When does the fiscal year end for InflaRx N-V?

  InflaRx N-V's fiscal year ends in December.

• Where is InflaRx N-V based?

  InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745

• What is InflaRx N-V's ISIN number?

  InflaRx N-V's international securities identification number is: NL0012661870

• What is InflaRx N-V's CUSIP number?

  InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101